Journal of Stem Cell Research

Genesis-JSCR-7(2)-90
Volume 7 | Issue 2
Open Access
ISSN: 2582-8797

A Systems-Level Therapeutic Platform Integrating Neural Progenitors, Mitochondrial Medicine, and Organ-Specific Biologics

Mike KS Chan [1,2,3], Michelle BF Wong [1,2], Krista Casazza [4] and Jonathan RT Lakey [2,4] *

[1.] European Wellness Academy, Klosterstrasse 205ID, 67480, Edenkoben, Germany
[2.] European Wellness BioMedical Group, Klosterstrasse 205ID, 67480, Edenkoben, Germany
[3.] Lincoln University College, Selangor, Malaysia
[4.] University of California, Irvine, Department of Surgery and Biomedical Engineering, Irvine CA, USA.

***Corresponding author:** Jonathan RT Lakey, European Wellness Academy, Klosterstrasse 205ID, 67480, Edenkoben, Germany

Citation: Chan MKS, Wong MBF, Casazza K, Lakey JRT. A Systems-Level Therapeutic Platform Integrating Neural Progenitors, Mitochondrial Medicine, and Organ-Specific Biologics. J Stem Cell Res. 7(2):1-14.

Received: July 05, 2026 | **Published**: July 20, 2026

Abstract

Traumatic spinal cord injury (SCI) remains one of the greatest challenges in regenerative medicine because neurological recovery is limited by complex interactions among neuronal loss, mitochondrial dysfunction, vascular compromise, chronic inflammation, extracellular matrix remodeling, and failure of endogenous repair. Although numerous regenerative strategies, including neural progenitor transplantation, mesenchymal stromal cells, biomaterial scaffolds, extracellular vesicles, and neuroprotective therapies, have demonstrated encouraging preclinical results, translation into consistent clinical benefit has been modest. These limitations suggest that SCI represents a systems-level failure of regeneration rather than a disorder that can be corrected through a single therapeutic modality. This review proposes an integrated systems regeneration framework that combines three complementary therapeutic domains: (1) developmentally specified neural precursor/progenitor cells to promote anatomically appropriate circuit reconstruction and remyelination; (2) mitochondrial-directed therapeutics to restore bioenergetic competence, reduce secondary injury, and improve survival of both host and transplanted cells; and (3) organ-specific precursor/progenitor-derived regenerative biologics, including Nano Organo Peptides (NOPs) and Mito Organelle (MO) preparations, to restore tissue-contextual signaling governing immune regulation, angiogenesis, extracellular matrix remodeling, and endogenous repair.

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

We discuss the biological rationale for each modality and examine how their coordinated application may better address the multidimensional pathophysiology of SCI than individual approaches alone. The European Wellness regenerative platform is presented as a hypothesis-driven translational model that integrates these complementary regenerative strategies. Future progress will require rigorous molecular characterization of regenerative biologics, standardized potency assays, biomarker development, and well-designed clinical trials to determine whether systems-based regenerative therapies can achieve durable functional recovery after SCI.

Keywords

Mitochondrial medicine; Organ-Specific Biologics; Biological rationale; Mesenchymal stromal cell

Introduction

Traumatic spinal cord injury (SCI) remains one of the most devastating disorders of the central nervous system (CNS), resulting in permanent disruption of motor, sensory, and autonomic pathways that profoundly alters virtually every aspect of human health [1]. Although considerable advances have been achieved in trauma systems, emergency neurosurgical care, intensive care medicine, and multidisciplinary rehabilitation over the past three decades, meaningful neurological recovery following moderate-to-severe SCI remains uncommon, and no pharmacologic, biologic, or regenerative intervention has yet demonstrated consistent restoration of functional spinal circuitry in large randomized clinical trials [2]. Consequently, SCI continues to represent one of the greatest unmet needs in regenerative neuroscience, imposing lifelong neurological disability together with extraordinary medical, psychological, social, and economic burdens on patients, caregivers, and healthcare systems worldwide [2,4].

Recent global burden of SCI analyses estimate that more than 15 million individuals worldwide are currently living with SCI, with hundreds of thousands of new traumatic and non-traumatic injuries occurring annually5. Although age-standardized incidence has remained relatively stable over recent decades, absolute prevalence continues to increase because of improved acute survival, population aging, and demographic transitions that have shifted SCI toward older adults with increasingly complex medical comorbidities5. Falls have now surpassed motor vehicle collisions as the leading cause of SCI in many high-income countries, whereas road traffic injuries remain predominant in low- and middle-income regions, highlighting substantial geographic heterogeneity in injury mechanisms and prevention priorities6. These epidemiologic transitions have important biological implications, as aging is itself accompanied by declining mitochondrial function, impaired endogenous regenerative capacity, chronic low-grade inflammation, and diminished neural plasticity, all of which may further constrain recovery following SCI7.

While paralysis represents the cornerstone manifestation of SCI, chronic neurological impairment initiates a cascade of systemic complications involving every organ system. SCI is associated with cardiovascular dysfunction, respiratory compromise, neurogenic bladder and bowel dysfunction, osteoporosis, metabolic syndrome, chronic pain, spasticity, recurrent infections, pressure injuries, endocrine abnormalities, accelerated sarcopenia, and profound psychological morbidity8. These secondary complications shorten life expectancy and contribute to diminished health-related quality of life even among individuals with neurologically incomplete injuries. Economic analyses consistently demonstrate lifetime healthcare expenditures reaching several million dollars for individuals with high cervical injuries when direct medical costs, rehabilitation, assistive technologies, long-term institutional care, caregiver

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

burden, and lost productivity are considered. Consequently, SCI represents not only a neurological disorder but also a chronic multisystem disease requiring lifelong medical management and imposing substantial societal costs9. Despite this enormous burden, therapeutic progress has been remarkably limited. Current standards of care remain supportive and focus on preventing further neurological deterioration through early spinal stabilization, optimization of spinal cord perfusion, intensive rehabilitation, and management of chronic complications. While advances in rehabilitation engineering, epidural stimulation, brain-computer interfaces, and neuroprosthetic technologies have produced encouraging improvements in selected functional domains, these approaches exploit residual neural circuitry rather than reconstructing damaged spinal networks. Similarly, numerous neuroprotective agents that demonstrated efficacy in experimental models have failed to produce reproducible neurological benefit in clinical trials, underscoring the substantial translational gap between preclinical discovery and clinical implementation [10,13].

The persistent failure of regenerative therapies reflects a fundamental misconception that has historically shaped SCI research. For decades, SCI was viewed primarily as an irreversible mechanical lesion in which the magnitude of neurological impairment was determined largely by the initial traumatic insult [14]. Contemporary evidence has fundamentally revised this paradigm. It is now widely recognized that the primary mechanical injury represents only the initiating event in a complex and evolving biological process that extends from minutes after trauma through months and even years of chronic disease progression15. Rather than a static lesion, SCI is increasingly understood as a dynamic systems disorder characterized by progressive interactions among neuronal death, mitochondrial dysfunction, vascular compromise, immune activation, extracellular matrix remodeling, and failure of endogenous regenerative programs. The primary injury consists of immediate mechanical disruption of neurons, oligodendrocytes, astrocytes, endothelial cells, and axons caused by compression, contusion, distraction, laceration, or ischemia[15,16]. Although this initial structural damage is largely irreversible, it accounts for only a fraction of the ultimate neurological deficit1,16. Within minutes, secondary injury mechanisms amplify tissue destruction through a highly coordinated cascade involving glutamate-mediated excitotoxicity, intracellular calcium overload, mitochondrial depolarization, oxidative and nitrosative stress, lipid peroxidation, blood-spinal cord barrier disruption, inflammatory cytokine release, complement activation, leukocyte infiltration, and progressive apoptosis of neurons and oligodendrocytes [17]. These processes evolve over hours to weeks and ultimately transition into a chronic phase characterized by persistent neuroinflammation, demyelination, axonal dieback, extracellular matrix remodeling, fibrotic and astroglial scar formation, and failure of axonal regeneration [17].

Among these interconnected processes, mitochondrial dysfunction has emerged as a central organizing mechanism linking acute cellular injury to chronic neurodegeneration18. Neurons depend almost exclusively on mitochondrial oxidative phosphorylation to sustain ATP production required for membrane excitability, axonal transport, synaptic transmission, calcium buffering, and neurotransmitter recycling[19]. Following SCI, excessive glutamate release produces prolonged activation of ionotropic glutamate receptors, resulting in pathological calcium influx that overwhelms mitochondrial buffering capacity [17]. Calcium overload promotes opening of the mitochondrial permeability transition pore, collapse of mitochondrial membrane potential, impaired oxidative phosphorylation, and excessive

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

production of reactive oxygen species [20]. Mitochondrial damage subsequently amplifies inflammatory signaling through release of mitochondrial damage-associated molecular patterns (mtDAMPs), activation of inflammasome pathways, disruption of mitophagy, and metabolic reprogramming of resident microglia and infiltrating macrophages [21]. Consequently, mitochondria function not merely as passive victims of injury but as central regulators of neuronal survival, immune activation, vascular integrity, and regenerative competence.

Among these interconnected processes, mitochondrial dysfunction has emerged as a central organizing mechanism linking acute cellular injury to chronic neurodegeneration [18]. Neurons depend almost exclusively on mitochondrial oxidative phosphorylation to sustain ATP production required for membrane excitability, axonal transport, synaptic transmission, calcium buffering, and neurotransmitter recycling [19]. Following SCI, excessive glutamate release produces prolonged activation of ionotropic glutamate receptors, resulting in pathological calcium influx that overwhelms mitochondrial buffering capacity [17]. Calcium overload promotes opening of the mitochondrial permeability transition pore, collapse of mitochondrial membrane potential, impaired oxidative phosphorylation, and excessive production of reactive oxygen species [20]. Mitochondrial damage subsequently amplifies inflammatory signaling through release of mitochondrial damage-associated molecular patterns (mtDAMPs), activation of inflammasome pathways, disruption of mitophagy, and metabolic reprogramming of resident microglia and infiltrating macrophages [21]. Consequently, mitochondria function not merely as passive victims of injury but as central regulators of neuronal survival, immune activation, vascular integrity, and regenerative competence.

As SCI progresses to the chronic phase, the regenerative microenvironment becomes progressively refractory to repair. Developmental signaling is lost, neurovascular coupling deteriorates, inhibitory extracellular matrix components and glial scarring restrict axonal growth, mitochondrial dysfunction sustains bioenergetic failure, and chronic neuroinflammation perpetuates tissue damage and limits endogenous repair. Collectively, these interconnected processes impair the survival, differentiation, and functional integration of both endogenous neural progenitors and transplanted cells, despite their intrinsic regenerative capacity [12,22,23]. Although current regenerative strategies, including NPC transplantation, biomaterial scaffolds, neurotrophic factor delivery, gene therapy, extracellular vesicles (EVs), and neuromodulation have each demonstrated therapeutic promise, most target only isolated aspects of this complex biology. Consequently, improvements in histological or cellular outcomes have translated into comparatively modest functional recovery in clinical studies [22,24]. These observations support a growing consensus that SCI is not simply a disorder of neuronal loss, but a systems-level failure of tissue regeneration requiring coordinated restoration of developmental signaling, mitochondrial function, neurovascular integrity, immune homeostasis, and extracellular matrix remodeling. This systems perspective provides the rationale for the integrated regenerative framework proposed in this review. Regionally specified neural progenitor cells address anatomical circuit reconstruction, mitochondrial-directed therapeutics preserve bioenergetic competence and reduce secondary degeneration, and organ-specific precursor/progenitor-derived biologics are proposed to restore tissue-specific regenerative signaling within the injury microenvironment. By targeting these complementary mechanisms concurrently, this multimodal strategy seeks to overcome the principal biological barriers that have

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

historically limited successful translation of regenerative therapies for SCI.

The Regenerative Plateau and Rationale for Systems Regeneration

Multiple regenerative platforms have demonstrated biological activity in experimental SCI, confirming that the adult spinal cord retains greater capacity for repair than previously recognized. Nevertheless, meaningful neurological recovery remains inconsistent, and no regenerative intervention has reproducibly restored functional spinal circuitry across heterogeneous clinical populations. This translational plateau reflects the biological complexity of SCI rather than the absence of therapeutic activity. Current approaches generally address individual components of repair while leaving interconnected metabolic, inflammatory, vascular, extracellular matrix, and developmental barriers unresolved [25–27]. Neural stem and progenitor cell transplantation illustrates this limitation. Transplanted cells can provide neuronal and glial substrates for remyelination, trophic support, and circuit reconstruction, but durable recovery requires more than graft survival. Donor cells must retain lineage fidelity, differentiate into appropriate neuronal and glial subtypes, extend anatomically directed axons, establish stable synapses, and form functional host–graft–host relay circuits within pre-existing spinal networks [28,29]. These processes are strongly influenced by developmental identity. HOX-dependent rostrocaudal specification and morphogen-directed patterning establish transcriptional programs governing neuronal subtype identity, axon-guidance receptor expression, synaptic partner selection, and network integration. Accordingly, spinally specified neural progenitors demonstrate more effective corticospinal regeneration and relay formation than developmentally mismatched neural populations, supporting a transition from generic cell transplantation toward developmentally informed regenerative neurobiology [10].

Cellular competence alone, however, is insufficient if the host tissue remains biologically non-permissive. The chronically injured spinal cord is characterized by persistent mitochondrial dysfunction, oxidative stress, vascular insufficiency, innate immune activation, and inhibitory extracellular matrix remodeling. These processes are mechanistically coupled: mitochondrial failure promotes inflammatory signaling and cell death; inflammation impairs mitochondrial quality control; vascular dysfunction intensifies bioenergetic stress; and scar-associated matrix remodeling restricts axonal extension [30]. Consequently, transplanted cells are introduced into an environment that compromises their survival, differentiation, maturation, and functional integration despite preserved intrinsic developmental potential.

Successful regeneration therefore requires reconstruction of the broader biological environment that supports neural development and repair. During embryogenesis, spinal cord formation depends on coordinated interactions among morphogen gradients, mitochondrial metabolism, vascular development, extracellular matrix organization, immune regulation, and reciprocal signaling between progenitor cells and their niche. In chronic SCI, disruption of these interdependent systems creates conditions that are fundamentally incompatible with sustained regeneration. Emerging evidence that EVs, mitochondrial signals, and circulating factors mediate communication among neural, vascular, stromal, and immune populations further supports the view that repair is governed by coordinated multicellular networks rather than isolated pathways[31] .On this basis, we propose an integrated regenerative framework comprising three complementary domains. First, regionally specified neural precursor/progenitor cells

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

provide developmentally matched neuronal and glial populations capable of supporting circuit reconstruction and host–graft integration. Second, mitochondrial-directed interventions seek to restore bioenergetic capacity, redox balance, calcium handling, and mitochondrial quality control in both injured host tissue and transplanted cells. Third, organ-specific precursor/progenitor-derived peptide and protein biologics are proposed to supply tissue-contextual signals that modulate inflammation, angiogenesis, extracellular matrix remodeling, metabolism, and endogenous repair. The central hypothesis is that coordinated restoration of developmental identity, mitochondrial competence, and a permissive regenerative niche will produce greater and more durable functional recovery than targeting any component independently.

Current regenerative therapies provide complementary, but incomplete, mechanisms of repair.

NPCs provide the cellular substrate for circuit reconstruction and remyelination but remain limited by graft survival, long-distance connectivity, and functional integration [32]. MSCs primarily exert paracrine immunomodulatory and trophic effects, whereas Schwann cells and olfactory ensheathing cells promote axonal growth and remyelination without reconstructing organized spinal circuitry [33]. Biomaterial scaffolds improve cell retention, extracellular matrix remodeling, and localized delivery of regenerative cues, while extracellular vesicles, gene therapies, and targeted molecular approaches modulate inflammation, mitochondrial function, and neuronal survival [34]. Collectively, these advances demonstrate that no single modality adequately addresses the structural, metabolic, vascular, immunological, and developmental determinants of spinal cord regeneration, providing the rationale for multimodal therapeutic platforms that integrate complementary mechanisms of repair. This mechanistic complementarity provides the rationale for developmentally informed, organ-specific regenerative biologics designed to restore tissue-contextual signaling within the injured spinal cord.



DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

Figure 1: Systems regeneration framework for spinal cord injury. Traumatic spinal cord injury (SCI) initiates interconnected secondary injury processes, including mitochondrial dysfunction, inflammation, extracellular matrix (ECM) remodeling, and loss of developmental signaling, which collectively create a metabolically compromised and non-permissive environment for repair. The proposed systems regeneration framework integrates three complementary therapeutic pillars. Mitochondrial-directed therapeutics seek to restore cellular bioenergetics, reduce oxidative stress, improve mitochondrial quality control, and enhance the survival of host and transplanted cells. Organ-specific regenerative biologics, including Nano Organo Peptides (NOPs) and Mito Organelle (MO) preparations, are proposed to restore tissue-contextual signaling that regulates immune activity, angiogenesis, ECM remodeling, and endogenous repair. Abbreviations: ECM, extracellular matrix; MO, Mito Organelle; NOPs, Nano Organo Peptides; SCI, spinal cord injury.

Organ-specific precursor/progenitor-derived regenerative biologics

Growing evidence indicates that the therapeutic activity of many stem cell–based interventions is mediated through paracrine mechanisms rather than durable engraftment. Secreted proteins, extracellular vesicles, regulatory RNAs, lipids, metabolites, and bioactive peptides collectively influence inflammation, angiogenesis, mitochondrial function, extracellular matrix remodeling, and activation of endogenous repair pathways [35]. These observations have established the regenerative secretome as a central mechanism underlying contemporary regenerative medicin [36]. Notably, regenerative signaling is not generic but reflects developmental origin. During embryogenesis, lineage-specific transcriptional programs establish tissue-specific secretory phenotypes that persist within precursor and progenitor populations [37]. Consequently, neural, cardiac, hepatic, renal, and other tissue-derived biologics contain distinct repertoires of proteins, extracellular vesicles, and regulatory molecules that mirror the physiological functions of their tissue of origin [3,5]. This developmental framework provides the biological rationale for organ-specific precursor/progenitor-derived biologics. Rather than functioning as single-target therapeutics, these preparations are designed to restore components of the coordinated signaling networks that govern tissue maintenance and regeneration. This strategy encompasses regionally specified precursor/progenitor cells, tissue-derived peptide fractions, Nano Organo Peptides (NOPs), and Mito Organelle (MO) preparations, each intended to complement cellular replacement by restoring tissue-contextual regenerative signaling. Although their molecular composition and mechanisms require further characterization, this systems-based approach is biologically consistent with current understanding of developmental biology, extracellular vesicle signaling, and regenerative medicine. The following section presents the European Wellness regenerative platform as an example of how systems-level regenerative principles may be operationalized within a unified translational framework.

European wellness as a translational platform for systems regeneration

Although each regenerative strategy addresses an important aspect of regeneration, few platforms have attempted to integrate these complementary mechanisms into a unified regenerative framework. The European Wellness (EW) research program represents one of the first coordinated efforts to operationalize this systems-based approach by combining developmentally specified precursor/progenitor cells, tissue-derived NOPs, and MO biologics within a common translational platform [38,41] Rather than functioning as independent interventions, these modalities are intended to address complementary biological processes governing tissue regeneration, including developmental signaling, mitochondrial homeostasis, immune regulation, vascular remodeling, extracellular matrix

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

organization, and endogenous repair. A defining feature of the EW platform is its emphasis on developmental identity as the basis of regenerative specificity. Contemporary developmental biology demonstrates that organogenesis establishes stable transcriptional, epigenetic, and secretory programs that continue to define tissue function throughout life. Precursor and progenitor cells from neural, cardiovascular, hepatic, renal, gastrointestinal, endocrine, reproductive, and musculoskeletal tissues exhibit distinct secretomes, extracellular vesicle cargo, and metabolic phenotypes reflecting their developmental origin. EW's organ-specific precursor/progenitor cell program is founded on the hypothesis that these developmentally encoded molecular programs can be therapeutically leveraged to restore tissue-specific regenerative signaling rather than simply replacing damaged cells. Although this hypothesis requires continued molecular validation using quantitative proteomics, extracellular vesicle profiling, and spatial transcriptomics, it is consistent with current understanding of developmental biology and regenerative secretome biology.

NOPs are proposed to capture low-molecular-weight bioactive peptide fractions derived from specific organs that participate in tissue-specific intercellular communication. Unlike conventional pharmacologic agents directed toward individual receptors or signaling pathways, NOPs are intended to provide coordinated biological cues that influence inflammation, angiogenesis, extracellular matrix remodeling, mitochondrial adaptation, and endogenous progenitor activity42–45. Across multiple EW investigations, organ-specific peptide formulations have been explored in neurological disorders, cardiovascular disease, metabolic dysfunction, reproductive aging, gastrointestinal health, and healthy aging, collectively supporting the concept that regenerative signaling is developmentally and tissue-context dependent rather than biologically generic. Although the active molecular constituents and potency determinants remain incompletely characterized, these studies provide an important translational framework for investigating tissue-derived peptide therapeutics using modern proteomic and systems biology approaches. Complementing tissue-specific signaling, MO biologics address one of the central mechanistic limitations of current SCI therapies: persistent mitochondrial dysfunction. Mitochondrial failure is increasingly recognized as a convergent driver of secondary injury, linking oxidative stress, calcium dysregulation, inflammatory activation, impaired axonal transport, oligodendrocyte dysfunction, and reduced neural progenitor survival. Conventional cell therapies are introduced into this metabolically compromised environment without directly correcting the underlying bioenergetic deficit, thereby limiting graft survival and functional integration. EW's MO platform is designed to restore mitochondrial homeostasis by supporting oxidative phosphorylation, reducing reactive oxygen species generation, improving mitophagy and mitochondrial quality control, and enhancing cellular metabolic resilience. While rigorous mechanistic validation remains necessary, this strategy directly addresses a biological process that is unaddressed by existing regenerative cell therapies and may improve both endogenous repair and transplanted cell performance within the chronically injured spinal cord.

The greatest strength of the EW platform lies not in any individual biologic but in its integration of complementary regenerative mechanisms. Regionally specified precursor/progenitor cells provide the anatomical substrate for neural circuit reconstruction; MO biologics target the metabolic environment required to sustain cellular survival and axonal regeneration; and NOPs are designed to restore tissue-specific molecular communication that coordinates immune resolution, vascular remodeling, extracellular

matrix organization, and endogenous repair. This system-level architecture closely mirrors the multidimensional biology of SCI, in which developmental identity, bioenergetic competence, and regenerative signaling are inseparable determinants of successful repair. Rather than viewing these modalities as competing therapeutic strategies, the EW platform proposes that durable regeneration will require their coordinated application within a unified biological framework. The EW platform should be viewed as a hypothesis-driven translational framework rather than a clinically validated therapeutic paradigm. Future studies should define the molecular composition of NOP and MO preparations using quantitative proteomics, metabolomics, lipidomics, extracellular vesicle characterization, and single-cell or spatial transcriptomics, while incorporating standardized potency assays, pharmacokinetic analyses, biomarker qualification, and randomized controlled clinical trials. As these technologies mature, the EW platform provides a testable roadmap for integrating developmental biology, mitochondrial medicine, and organ-specific regenerative signaling into precision regenerative therapeutics for SCI and other complex degenerative disorders.

Source tissue	Dominant regenerative signals	Primary biological functions	Potential relevance to SCI	Evidence level
Neural/CNS	Neurotrophic factors, synaptic proteins, neural EV cargo	Neuronal survival, axonal guidance, synaptic plasticity	Circuit reconstruction, remyelination	Preclinical
Placenta	Immunomodulatory proteins, pro-angiogenic factors, EVs	Immune resolution, angiogenesis, vascular repair	Remodeling the regenerative niche	Preclinical/Early clinical
Cardiac	Angiogenic and mitochondrial regulators	Vascular remodeling, bioenergetics	Secondary tissue preservation	Mechanistic
Liver	Metabolic and stress-response proteins	Metabolic homeostasis, antioxidant defense	Systemic metabolic support	Mechanistic
Kidney	Anti-inflammatory and epithelial repair mediators	Oxidative stress reduction, tissue repair	Systemic recovery	Emerging
Reproductive tissues	Endocrine and mitochondrial regulators	Angiogenesis, endocrine signaling	Supportive regenerative biology	Emerging

Table1: Developmental Origin Determines the Biological Functions of Organ-Specific Regenerative Biologics.

Therapy	Primary target	Strength	Limitation	Role in systems regeneration
Neural progenitor cells (NPCs)	Replacement of lost neurons and glia; remyelination; reconstruction of damaged neural circuits.	Directly provides a cellular substrate for neurogenesis, oligodendrogenesis, synaptic relay formation, and potentially long-distance circuit	Graft survival, lineage fidelity, axonal guidance, long-distance connectivity, and functional integration remain limited by the inflammatory, metabolic, vascular,	Restores the anatomical and cellular components required for circuit reconstruction but depends on complementary strategies that improve the host

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

		integration. Regionally specified cells can preserve spinal developmental identity.	and extracellular matrix environment of the injured spinal cord.	microenvironment and support metabolic competence.
Mitochondrial-directed therapeutics	Mitochondrial dysfunction, bioenergetic failure, oxidative stress, calcium dysregulation, and impaired mitochondrial quality control in host and transplanted cells.	Can preserve ATP production, reduce reactive oxygen species and secondary degeneration, improve cellular resilience, and support survival and maturation of endogenous and transplanted neural cells.	Cannot independently replace lost cells or reconstruct neural circuitry. Delivery, biodistribution, dosing, target engagement, and responses across injury stages require further definition.	Creates a bioenergetically permissive environment that supports neuronal survival, limits secondary injury, and increases the likelihood that cellular and biologic therapies will remain viable and functional.
Organ-specific regenerative biologics (NOPs and MO preparations)	Tissue-contextual signaling deficits affecting inflammation, angiogenesis, extracellular matrix remodeling, metabolism, neuroprotection, and endogenous repair.	Potentially provides coordinated, pleiotropic signals derived from organ- or precursor-specific biological programs rather than acting through a single molecular target.	Molecular composition, active constituents, mechanisms of action, pharmacokinetics, potency, batch consistency, safety, and clinical efficacy remain incompletely characterized and require rigorous validation.	Proposed to reprogram the injury microenvironment, restore tissue-specific regenerative communication, and synergize with neural progenitors and mitochondrial-directed interventions.
Integrated systems regeneration	Concurrent structural, metabolic, vascular, immune, extracellular matrix, and developmental barriers to spinal cord repair.	Aligns treatment with the multidimensional biology of SCI, permits mechanistic complementarity among modalities, and may provide greater potential for durable functional recovery than isolated interventions.	Introduces complexity in product characterization, sequencing, dosing, delivery, interaction testing, biomarker selection, and clinical trial design. Synergy must be demonstrated rather than assumed.	Coordinates circuit reconstruction, metabolic rescue, and restoration of a permissive regenerative niche to address upstream and downstream determinants of recovery within a unified therapeutic framework.

Table 2: Synthesis of Regenerative Modalities for Spinal Cord Injury.

Conclusion

Despite major advances in neural stem cell biology and regenerative neuroscience, SCI remains characterized by a persistent gap between encouraging experimental findings and meaningful clinical recovery. This disconnect reflects the multifactorial nature of SCI, in which durable regeneration depends not only on replacing lost cells but also on restoring the developmental, metabolic, vascular, immune, and extracellular matrix environments required to

DOI: https://doi.org/10.52793/JSCR.2026.7(2)-90

support long-term circuit reconstruction. Consequently, therapies directed at individual components of the regenerative process have produced important biological insights but only modest functional benefit. Emerging evidence supports a transition from reductionist regenerative approaches toward systems-level regenerative medicine. Rather than viewing neural progenitor transplantation, mitochondrial therapeutics, and tissue-derived biologics as independent interventions, these complementary modalities may collectively address the principal biological barriers that limit recovery after SCI. Developmentally specified neural progenitor cells provide the cellular substrate for anatomically appropriate circuit reconstruction, mitochondrial-directed therapies preserve the bioenergetic capacity necessary for neuronal survival and regeneration, and organ-specific biologics are proposed to restore tissue-contextual signaling that supports immune resolution, vascular remodeling, extracellular matrix organization, and endogenous repair. Together, these strategies align therapeutic intervention with the multidimensional biology of spinal cord regeneration. The EW regenerative platform represents a translational framework for integrating these complementary regenerative domains rather than a single therapeutic modality. By combining regionally specified precursor/progenitor cells with NOPs and MO biologics, the platform provides a biologically coherent and experimentally testable approach for investigating how developmental identity, mitochondrial homeostasis, and tissue-specific regenerative signaling interact to promote functional recovery. Although the molecular composition, mechanisms of action, and clinical efficacy of these biologics require rigorous validation, this integrated strategy addresses fundamental limitations that have historically constrained regenerative therapies for SCI. Future progress will depend on defining the molecular architecture of regeneration through quantitative proteomics, extracellular vesicle characterization, single-cell and spatial transcriptomics, metabolomics, standardized potency assays, biomarker qualification, and well-designed randomized clinical trials. These approaches will be essential for identifying the active components of complex regenerative biologics, validating mechanisms of action, and establishing biomarkers of target engagement and clinical response. Successful regeneration following SCI will require coordinated restoration of the regenerative ecosystem rather than correction of any single pathological process. By integrating developmental biology, mitochondrial medicine, and organ-specific regenerative signaling within a systems biology framework, next-generation regenerative therapies have the potential to move the field beyond incremental neuroprotection toward durable reconstruction of functional neural circuitry.

References

1. Mensah EO, Chalif JI, Johnston BR, et al. Traumatic spinal cord injury: a review of the current state of art and future directions - what do we know and where are we going? North Am Spine Soc J. 2025;22:100601.
2. Hu X, Xu W, Ren Y, et al. Spinal cord injury: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):245.
3. Grasso G, Cusimano L, Noto M, Maugeri R, Iacopino DG. Current and emergent therapies targeting spinal cord injury. Brain Spine. 2025;5:104243.
4. Hachem LD, Fehlings MG. Pathophysiology of Spinal Cord Injury. Neurosurg Clin N Am. 2021;32(3):305-313.
5. Kim M, Jeong W, Jang S, Park JH, Bae Y, Lee SW. Spinal Cord Injury Epidemiology and Causes: A Worldwide Analysis with 2050 Projections. Healthcare. 2025;13(20):2552.
6. Wu J, Zhong B, Pei X, Chen B, Fang R, Zhu Z. Global Burden of Spinal Cord Injuries Attributable to Falls and Road Traffic Injuries in Working-Age Individuals, 1990 to 2021, with Projections through 2040: An Age-Period-Cohort Analysis. Neuroepidemiology. Published online December 31, 2025:1-20.
7. Wang T, Zhang Z, Liu J, et al. Spinal Cord Injury and Ageing: The Role of Chronic Neuroinflammation. Aging Dis. 2025;17(4):2053-2074.
8. Martínez-Torija M, Esteban PF, Santos-De-La-Mata A, Castillo-Hermoso M, Molina-Holgado E, Moreno-Luna R. Multifaceted Pathophysiology and Secondary Complications of Chronic Spinal Cord Injury: Focus on Pressure Injury. J Clin Med. 2025;14(5):1556.

9. Moreno-González E, Ibarra A. The Critical Management of Spinal Cord Injury: A Narrative Review. Clin Pract. 2024;15(1):2.
10. Tian T, Zhang S, Yang M. Recent progress and challenges in the treatment of spinal cord injury. Protein Cell. 2023;14(9):635-652.
11. Mastrorilli V, Luvisetto S, Ruggieri V, et al. A translational preclinical strategy for chronic spinal cord injury: neuroprotective and regenerative potential of botulinum neurotoxin type A combined with muscle atrophy prevention via electrostimulation. Mil Med Res. 2026;13(1):100049.
12. An KD, Noh CY, Jang J, Yuh WT, Choi I. Potential Pharmacologic Treatments in Spinal Cord Injury: A Narrative Review. Korean J Neurotrauma. 2025;21(4):237-254.
13. Karri J, Doan J, Vangeison C, Catalanotto M, Nagpal AS, Li S. Emerging Evidence for Intrathecal Management of Neuropathic Pain Following Spinal Cord Injury. Front Pain Res. 2022;3:933422.
14. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front Neurol. 2019;10:282.
15. Lu Y, Jin J, Zhang H, et al. Traumatic brain injury: Bridging pathophysiological insights and precision treatment strategies. Neural Regen Res. 2026;21(3):887-907.
16. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front Neurol. 2019;10:282.
17. Hou J, Klippel K, Bose P. Glutamate Excitotoxicity: A Key Secondary Injury Mechanism of Traumatic Brain Injury and Spinal Cord Injury. Front Biosci. 2025;30(10):38904.
18. Schmidt J, Quintá HR. Mitochondrial dysfunction as a target in spinal cord injury: intimate correlation between pathological processes and therapeutic approaches. Neural Regen Res. 2023;18(10):2161-2166.
19. Flippo KH, Strack S. Mitochondrial dynamics in neuronal injury, development and plasticity. J Cell Sci. 2017;130(4):671-681.
20. Walkon LL, Strubbe-Rivera JO, Bazil JN. Calcium Overload and Mitochondrial Metabolism. Biomolecules. 2022;12(12):1891.
21. Brooks NAH, Riar I, Klegeris A. Mitochondrial damage-associated molecular patterns: Neuroimmunomodulators in central nervous system pathophysiology. Neural Regen Res. 2026;21(4):1322-1338.
22. Shafqat A, Albalkhi I, Magableh HM, Saleh T, Alkattan K, Yaqinuddin A. Tackling the glial scar in spinal cord regeneration: new discoveries and future directions. Front Cell Neurosci. 2023;17:1180825.
23. Ceto S, Sekiguchi KJ, Takashima Y, Nimmerjahn A, Tuszynski MH. Neural Stem Cell Grafts Form Extensive Synaptic Networks that Integrate with Host Circuits after Spinal Cord Injury. Cell Stem Cell. 2020;27(3):430-440.e5.
24. Hellenbrand DJ, Quinn CM, Piper ZJ, Morehouse CN, Fixel JA, Hanna AS. Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation. 2021;18(1):284.
25. Stewart AN, Gensel JC, Jones L, Fouad K. Challenges in Translating Regenerative Therapies for Spinal Cord Injury. Top Spinal Cord Inj Rehabil. 2023;29(Suppl):23-43. doi:10.46292/sci23-00044S
26. Wang T, Han Q, Lv S, et al. Research progress on the mechanisms of endogenous neural stem cell differentiation in spinal cord injury repair. Front Cell Neurosci. 2025;19:1592297. doi:10.3389/fncel.2025.1592297
27. Wu YY, Gao YM, Feng T, Rao JS, Zhao C. Enhancing Functional Recovery After Spinal Cord Injury Through Neuroplasticity: A Comprehensive Review. Int J Mol Sci. 2025;26(14):6596. doi:10.3390/ijms26146596
28. Fischer I, Dulin JN, Lane MA. Transplanting neural progenitor cells to restore connectivity after spinal cord injury. Nat Rev Neurosci. 2020;21(7):366-383.
29. Zipser CM, Cragg JJ, Guest JD, et al. Cell-based and stem-cell-based treatments for spinal cord injury:

evidence from clinical trials. Lancet Neurol. 2022;21(7):659-670. doi:10.1016/S1474-4422(21)00464-6

30. Marzetti E, Calvani R, Landi F, Coelho-Júnior HJ, Picca A. Mitochondrial Quality Control Processes at the Crossroads of Cell Death and Survival: Mechanisms and Signaling Pathways. Int J Mol Sci. 2024;25(13):7305.
31. Park JH, Back DB, Hamanaka G, Ishikane S, Hayakawa K. Extracellular vesicles and mitochondria in central nervous system diseases. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2026;46(2):171-184.
32. Hosseini SM, Stecina K, Nemati S, Wang RR, Zhang JV, Karimi-Abdolrezaee S. Circuit Reconstruction after Traumatic Spinal Cord Injury by Cellular and Pharmacological Approaches. J Neurosci Off J Soc Neurosci. 2025;45(35):e0362252025.
33. Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J Clin Med. 2019;8(7):1025.
34. Wang Y, Tan H, Hui X. Biomaterial Scaffolds in Regenerative Therapy of the Central Nervous System. BioMed Res Int. 2018;2018:7848901.
35. Wu Y, Toldo N, Fabbri M. The interplay between the extracellular matrix and extracellular vesicle-associated microRNAs. Cell Commun Signal CCS. 2026;24(1):89.
36. Gwam C, Mohammed N, Ma X. Stem cell secretome, regeneration, and clinical translation: a narrative review. Ann Transl Med. 2021;9(1):70.
37. Feyaerts D, Urbschat C, Gaudillière B, Stelzer IA. Establishment of tissue-resident immune populations in the fetus. Semin Immunopathol. 2022;44(6):747-766.
38. Chan MKS, Wong MBF, Pan S, et al. Carcinogenicity And Oncogenicity of Precursor/Progenitor Stem Cells of the Xenogeneic Origin: The Balb/C-3t3 Cell Transformation Assay. SSP Mod Pharm Med. 2025b;3(5):20-37.
39. Chan MKS, Wong MBF, Katz B, et al. Mass Spectrometry Analysis of OrganSpecific Cellular Extracts - Nanomized Organo Peptides: The Stability Study. J Stem Cell Res. Published online November 11, 2024.
40. Wellington A, Lakey JRT, Williams A, et al. Peptide Therapy Improves Mobility in Older and Large Breed Canines: A Case Study. J Biomed Sci. 2022;4(4).
41. Chan MKS, Wong MBF, Chernykh V, et al. View PDF Mitochondrial Peptides and Cell Extracts in Regenerative Medicine and Anti-Aging Therapies: Therapeutic Potential of Mito Organelles. J Stem Cell Res. 2025a;6(2):1-11.
42. Chan MKS, Lakey, Jonathan RT, Skutella T. Alzheimer's Disease: Innovative Approaches and Emerging Strategies in Holistic Management. Adv Clin Med Res. 2025;6(1).
43. Chan MKS, Wong MB, Casazza K, Lakey, Jonathan RT. Emerging Peptide Therapies for Kidney Disease: Focus on Nano-Organo and Mitochondria-Targeted Strategies. Am J Biomed Sci Res. 2025;27(3)
44. Chan MKS, Wong MB, Chernykh V, et al. Mitochondrial Peptides and Cell Extracts in Regenerative Medicine and Anti-Aging Therapies: Therapeutic Potential of Mito Organelles. J Stem Cell Res. 2025;6(2).
45. Chan MKS, Wong MBF, Casazza K, et al. Peptide-Based Precision Therapeutics for Cardiac Disease: Targeting Mitochondrial Dysfunction, Fibrosis, and Inflammation. Am J Biomed Sci Res. 2025;27(3)